Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | Director | April 14, 2021 | April 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date April 14, 2021 · Filed April 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 179,833 |
Reported balance
After 2021-04-14 transaction · row 1
1 source rowRow 1 · 2021-04-14 · Sale · Disposed 5,000 · Balance 179,833 F1: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 14, 2021 Filed Apr 14, 2021 20:19 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 5,000 | $45.00 | $225,000.00 |
DisclosureSEC source: 0001179110-21-004416 · edgar.xml · nonDerivative · entry 1 Kelley Kenneth J · CIK 0001291219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,833 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 01:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 500 | $46.08 | $23,042.00 |
DisclosureSEC source: 0001179110-21-002487 · edgar.xml · nonDerivative · entry 2 Kelley Kenneth J · CIK 0001291219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,833 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $45.91 to $46.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 01:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 4,500 | $45.26 | $203,675.40 |
DisclosureSEC source: 0001179110-21-002487 · edgar.xml · nonDerivative · entry 1 Kelley Kenneth J · CIK 0001291219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,333 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $44.90 to $45.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 01, 2021 Filed Feb 1, 2021 23:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 246 | $48.69 | $11,977.42 |
DisclosureSEC source: 0001179110-21-001008 · edgar.xml · nonDerivative · entry 2 Kelley Kenneth J · CIK 0001291219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,833 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $48.65 to $48.77. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 01, 2021 Filed Feb 1, 2021 23:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 4,754 | $48.09 | $228,616.53 |
DisclosureSEC source: 0001179110-21-001008 · edgar.xml · nonDerivative · entry 1 Kelley Kenneth J · CIK 0001291219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,079 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $47.64 to $48.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 04, 2021 Filed Jan 4, 2021 22:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 290 | $43.38 | $12,581.36 |
DisclosureSEC source: 0001179110-21-000059 · edgar.xml · nonDerivative · entry 2 Kelley Kenneth J · CIK 0001291219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,833 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $43.325 to $43.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 04, 2021 Filed Jan 4, 2021 22:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 4,710 | $42.88 | $201,974.22 |
DisclosureSEC source: 0001179110-21-000059 · edgar.xml · nonDerivative · entry 1 Kelley Kenneth J · CIK 0001291219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,123 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $42.33 to $43.305. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 07, 2020 Filed Dec 7, 2020 23:05 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 35,086 | $41.00 | $1,438,526.00 |
DisclosureSEC source: 0001179110-20-011734 · edgar.xml · nonDerivative · entry 1 Kelley Kenneth J · CIK 0001291219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,833 Read SEC document |
| December 02, 2020 Filed Dec 2, 2020 22:55 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 31,792 | $41.00 | $1,303,472.00 |
DisclosureSEC source: 0001179110-20-011550 · edgar.xml · nonDerivative · entry 1 Kelley Kenneth J · CIK 0001291219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,919 Read SEC document |
| November 27, 2020 Filed Nov 27, 2020 22:43 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $41.25 | $412,500.00 |
DisclosureSEC source: 0001179110-20-011448 · edgar.xml · nonDerivative · entry 2 Kelley Kenneth J · CIK 0001291219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,711 Read SEC document |
| November 25, 2020 Filed Nov 27, 2020 22:43 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 9,671 | $41.50 | $401,350.37 |
DisclosureSEC source: 0001179110-20-011448 · edgar.xml · nonDerivative · entry 1 Kelley Kenneth J · CIK 0001291219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,711 F1 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $41.50 to $41.5102. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 30, 2020 Filed May 1, 2020 23:12 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 8,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005379 · edgar.xml · nonDerivative · entry 1 Kelley Kenneth J · CIK 0001291219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,382 F1 · shares: Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 30, 2021 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| March 19, 2020 Filed Mar 19, 2020 23:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | PurchaseCommon Stock | 17,543 | $14.24 | $249,780.74 |
DisclosureSEC source: 0001179110-20-003999 · edgar.xml · nonDerivative · entry 3 Kelley Kenneth J · CIK 0001291219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,553 F3 · price: Represents a weighted average purchase price per share. These shares were purchased at prices ranging from $14.15 to $14.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
| March 19, 2020 Filed Mar 19, 2020 23:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | PurchaseCommon Stock | 17,543 | $14.25 | $249,982.49 |
DisclosureSEC source: 0001179110-20-003999 · edgar.xml · nonDerivative · entry 2 Kelley Kenneth J · CIK 0001291219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,010 F2 · price: Represents a weighted average purchase price per share. These shares were purchased at prices ranging from $14.23 to $14.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
| March 19, 2020 Filed Mar 19, 2020 23:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | PurchaseCommon Stock | 17,543 | $14.19 | $248,933.42 |
DisclosureSEC source: 0001179110-20-003999 · edgar.xml · nonDerivative · entry 1 Kelley Kenneth J · CIK 0001291219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,467 F1 · price: Represents a weighted average purchase price per share. These shares were purchased at prices ranging from $14.11 to $14.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
| May 02, 2019 Filed May 3, 2019 20:17 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 12,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005506 · edgar.xml · nonDerivative · entry 1 Kelley Kenneth J · CIK 0001291219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,924 F1 · shares: Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 2, 2020 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 02, 2018 Filed May 2, 2018 23:41 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 10,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006089 · edgar.xml · nonDerivative · entry 1 Kelley Kenneth J · CIK 0001291219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,751 F1 · shares: Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 2, 2019 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 04, 2017 Filed May 5, 2017 20:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 14,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-006699 · edgar.xml · nonDerivative · entry 1 Kelley Kenneth J · CIK 0001291219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,388 F1 · shares: Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 4, 2018 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.